GlassScriptPhysician profile
Johnny U Franco
NPI 1053503672
$61,632.11
in general payments reported to CMS, 2019-2025
15 companies · $36K in 2025
The $36K reported for 2025 was more than what 98% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,054 · 2020: $623 · 2021: $2,462 · 2022: $1,587 · 2023: $1,089 · 2024: $13K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $4,972 · Travel and Lodging: $3,344 · Long Term Medical Supply Or Device Loan: $326 · Gift: $87.00 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,668.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,500.00 |
| Food and Beverage | $4,972.11 |
| Travel and Lodging | $3,344.01 |
| Long Term Medical Supply Or Device Loan | $325.80 |
| Gift | $87.00 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,950.01 | 2023-2025 | |
| Galderma Laboratories, L.P. | $18,509.13 | 2021-2025 | Dysport |
| Merz North America, INC. | $9,295.51 | 2019-2025 | Xeomin |
| Motiva USA, LLC | $8,413.48 | 2024-2025 | |
| Integra Lifesciences Corporation | $1,843.39 | 2024-2025 | Integra, Durasorb Monofilament Mesh, Omnigraft |
| Tela Bio, INC. | $1,734.57 | 2023-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Allergan, INC. | $1,115.45 | 2019-2022 | |
| Revance Therapeutics, INC. | $468.62 | 2024-2025 | Daxxify, Daxi |
| Sientra, INC. | $357.89 | 2019-2022 | |
| Davol INC. | $289.51 | 2022 | |
| Tepha INC | $250.56 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $179.36 | 2019-2022 | |
| Mentor Worldwide LLC | $132.95 | 2022 | |
| Apyx Medical Corporation | $53.68 | 2019-2020 | |
| Musculoskeletal Transplant Foundation INC. | $38.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Franco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.